Skip to main content
SpringerLink
Log in

Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Clofarabine increases the activation of 1-β-d-arabinofuranosyl cytosine (araC) in tumor cells, and combination of these two drugs has been shown to result in good clinical activity against various hematologic malignancies. 1-β-d-[4-thio-arabinofuranosyl] cytosine (T-araC) is a new cytosine analog that has exhibited excellent activity against a broad spectrum of human solid tumors and leukemia/lymphoma xenografts in mice and is currently being evaluated in patients as a new drug for the treatment of cancer. Since T-araC has a vastly superior preclinical efficacy profile in comparison to araC, we have initiated studies to determine the potential value of clofarabine/T-araC combination therapy.

Methods

In vitro studies have been conducted to determine the effect of clofarabine on the metabolism of T-araC, and in vivo studies have been conducted to determine the effect of the clofarabine/T-araC combination on five human tumor xenografts in mice.

Results

Initial studies with various tumor cells in culture indicated that a 2-h incubation with clofarabine enhanced the metabolism of T-araC 24 h after its removal by threefold in three tumor cell types (HCT-116 colon, K562 leukemia, and RL lymphoma) and by 1.5-fold in two other tumor cell types (MDA-MB-435 breast (melanoma), and HL-60 leukemia). Pretreatment with clofarabine resulted in a slight decrease in metabolism of T-araC in RPMI-8226 myeloma cells (65% of control) and inhibited metabolism of T-araC in CCRF-CEM leukemia cells by 90%. In vivo combination studies were conducted with various human tumor xenografts to determine whether or not the modulations observed in vitro were reflective of the in vivo situation. Clofarabine and T-araC were administered on alternate days for five treatments each (q2dx5) with the administration of T-araC 24 h after each clofarabine treatment. Combination treatment of HCT-116, K562, HL-60, or RL tumors with clofarabine and T-araC resulted in dramatically superior anti-tumor activity than treatment with either agent alone, whereas this combination resulted in antagonism in CCRF-CEM tumors. The in vivo antitumor activity of clofarabine plus T-araC against HCT-116 tumors was much better than the activity seen with clofarabine plus araC.

Conclusions

These studies provide a rationale for clinical trials using this combination in the treatment of acute leukemias as well as solid tumors and suggest that this combination would exhibit greater antitumor activity than that of clofarabine plus araC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA III, Weitman S (2006) Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5:855–863

    Article  PubMed  CAS  Google Scholar 

  2. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM (2005) The role of clofarabine in hematologic and solid malignancies—development of a next-generation nucleoside analog. Cancer 103:1985–1995

    Article  PubMed  CAS  Google Scholar 

  3. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S (2007) Clofarabine: past, present, and future. Leuk Lymphoma 48:1922–1930

    Article  PubMed  CAS  Google Scholar 

  4. Cooper T, Ayres M, Nowak B, Gandhi V (2005) Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 55:361–368

    Article  PubMed  CAS  Google Scholar 

  5. Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H (2005) Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940–947

    Article  PubMed  CAS  Google Scholar 

  6. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O’Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45–51

    Article  PubMed  CAS  Google Scholar 

  7. Gidwani P, Ramesh KH, Liu Y, Kolb EA (2008) The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy 54:120–124

    Article  PubMed  CAS  Google Scholar 

  8. Tiwari KN, Shortnacy-Fowler AT, Cappellacci L, Parker WB, Waud WR, Montgomery JA, Secrist JA III (2000) Synthesis of 4′-thio-β-d-arabinofuranosyl-cytosine (4′-thio-ara-C) and comparison of its anticancer activity with that of ara-C. Nucleosides Nucleotides Nucleic Acids 19:329–340

    Article  PubMed  CAS  Google Scholar 

  9. Waud WR, Gilbert KS, Shepherd RV, Montgomery JA, Secrit JA III (2003) Preclinical antitumor activity of 4′-thio-beta-d-arabinofuranosylcytosine (4′-thio-ara-C). Cancer Chemother Pharmacol 51:422–426

    PubMed  CAS  Google Scholar 

  10. Waud WR, Shepherd RV, Gilbert KS, Tiwari KN, Secrist JA III (2004) Precinical antitumor activity of 4′-thio-β-d-arabinofuranosylcytosine (4′-thio-ara-C, OSI-7836) in human leukemia and lymphoma xenograft models. Proc Am Assoc Cancer Res 45:714

    Google Scholar 

  11. Parker WB, Shaddix SC, Rose LM, Waud WR, Shewach DS, Tiwari KN, Secrist JA III (2000) Metabolism of 4′-thio-β-d-arabinofuranosylcytosine in CEM cells. Biochem Pharmacol 60:1925–1932

    Article  PubMed  CAS  Google Scholar 

  12. Richardson F, Black C, Richardson K, Franks A, Wells E, Karimi S, Sennello G, Hart K, Meyer D, Emerson D, Brown E, LeRay J, Nilsson C, Tomkinson B, Bendele R (2005) Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. Cancer Chemother Pharmacol 55:213–221

    Article  PubMed  CAS  Google Scholar 

  13. Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE (2006) The role of human nucleoside transporters in cellular uptake of 4′-thio-beta-d-arabinofuranosylcytosine and beta-d-arabinosylcytosine. Mol Pharmacol 70:303–310

    PubMed  CAS  Google Scholar 

  14. Richardson KA, Vega TP, Richardson FC, Moore CL, Rohloff JC, Tomkinson B, Bendele RA, Kuchta RD (2004) Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. Biochem Pharmacol 68:2337–2346

    Article  PubMed  CAS  Google Scholar 

  15. Someya H, Shaddix SC, Tiwari KN, Secrist JA III, Parker WB (2003) Phosphorylation of 4′-thio-β-d-arabinofuranosylcytosine and its analogs by human deoxycytidine kinase. J Pharmacol Exp Ther 304:1314–1322

    Article  PubMed  CAS  Google Scholar 

  16. Someya H, Waud WR, Parker WB (2006) Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine. Cancer Chemother Pharmacol 57:772–780

    Article  PubMed  CAS  Google Scholar 

  17. Thottassery JV, Westbrook L, Someya H, Parker WB (2006) c-Abl-independent p73 stabilization during gemcitabine- or 4′-thio-beta-d-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther 5:400–410

    Article  PubMed  CAS  Google Scholar 

  18. Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group (2006) A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemother Pharmacol 58:703–710

    Article  PubMed  CAS  Google Scholar 

  19. Lee CP, de Jonge MJ, O’Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J (2006) A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin Cancer Res 12:2841–2848

    Article  PubMed  CAS  Google Scholar 

  20. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR, Simpson-Herren L, Griswold DP Jr (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel Karger 42:1–22

    Google Scholar 

  21. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W (2003) Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9:6335–6342

    PubMed  CAS  Google Scholar 

  22. Waud WR, Schmid SM, Montgomery JA, Secrist JA III (2000) Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) adenine (Cl–F-ara-A). Nucleosides Nucleotides Nucleic Acids 19:447–460

    Article  PubMed  CAS  Google Scholar 

  23. Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnancy AT, Montgomery JA, Secrist JA III, Bennett LL Jr (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5-triphosphate. Cancer Res 51:2386–2394

    PubMed  CAS  Google Scholar 

  24. Xie C, Plunkett W (1995) Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55:2847–2852

    PubMed  CAS  Google Scholar 

  25. Parker WB, Shaddix SC, Rose LM, Shewach DS, Hertel LW, Secrist JA III, Montgomery JA, Bennett LL Jr (1999) Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-d-ribofuranosyl) adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-d-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 55:515–520

    PubMed  CAS  Google Scholar 

  26. Spasokoukotskaja T, Sasvári-Székely M, Keszler G, Albertioni F, Eriksson S, Staub M (1999) Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur J Cancer 35:1862–1867

    Article  PubMed  CAS  Google Scholar 

  27. Csapó Z, Sasvári-Székely M, Spasokoukotskaja T, Talianidis I, Eriksson S, Staub M (2001) Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem Pharmacol 61:191–197

    Article  PubMed  Google Scholar 

  28. Keszler G, Spasokoukotskaja T, Sasvári-Székely M, Eriksson S, Staub M (2006) Deoxycytidine kinase is reversibly phosphorylated in normal human lymphocytes. Nucleosides Nucleotides Nucleic Acids 25:1147–1151

    Article  PubMed  CAS  Google Scholar 

  29. Qian M, Wang X, Shanmuganathan K, Chu CK, Gallo JM (1994) Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) adenine in rats. Cancer Chemother Pharmacol 33:484–488

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by NCI Grant P01 CA 34200.

Author information

Authors and Affiliations

  1. Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA

    William B. Parker, Sue C. Shaddix, Karen S. Gilbert, Rodney V. Shepherd & William R. Waud

Authors
  1. William B. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sue C. Shaddix
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen S. Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rodney V. Shepherd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William R. Waud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William B. Parker.

Additional information

Disclosure: Clofarabine and T-araC were discovered at Southern Research Institute, which receives licensing fees and royalty payments from the commercial development and use of these agents. Southern Research Institute does distribute some of this money to Drs. Parker and Waud.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, W.B., Shaddix, S.C., Gilbert, K.S. et al. Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine. Cancer Chemother Pharmacol 64, 253–261 (2009). https://doi.org/10.1007/s00280-008-0862-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0862-z

Keywords

Search

Navigation